What a year 2015 was for the myelomatologist!

The U.S. Food and Drug Admin­istra­tion (FDA) ap­prov­al of three new myeloma drugs, all within the span of a few weeks to­wards the end of the year, had already gen­er­ated great ex­cite­ment in the com­munity.

Then, sev­er­al poten­tial prac­tice-changing pre­sen­ta­tions at the 2015 American Society of He­ma­tol­ogy (ASH) annual meeting put the proverbial icing on the cake to round out a landmark year for myeloma thera­peutics.

This edition of the myeloma quiz …

The American Society of Clinical Oncology (ASCO) meeting in any given year is hit-or-miss as far as breaking research for multiple myeloma goes.

However, at ASCO 2015, there were no two views among myeloma experts. It was probably one of the most sig­nif­i­cant ASCO meetings as far as pre­senta­tions of abstracts that have the poten­tial to alter the land­scape of myeloma treat­ment in the near future.

There is no way to do justice to all the presentations at ASCO …

A new year is upon us.  I hope it has started well for everybody, and that all had a great holiday season!

The last few weeks of 2014 were a hap­pen­ing time for the mul­ti­ple myeloma com­munity. The short span of time witnessed the pub­li­ca­tion of up­dated criteria for the diag­nosis of mul­ti­ple myeloma from the Inter­na­tional Myeloma Work­ing Group (IMWG). In addi­tion, the 56^th annual meeting of the American Society of He­ma­tol­ogy (ASH) took place in San Francisco, with …

It’s July, and we have had some time to digest the findings from the American Society of Clinical Oncology (ASCO) annual meeting held in Chicago May 30 through June 3.

Quite a few pre­sen­ta­tions caught one’s eye.

We finally saw the results of the much awaited PANORAMA-1 study in­ves­ti­gating the efficacy and safety of panobinostat (LBH589) plus Velcade and dexa­meth­a­sone com­pared to Velcade and dexa­meth­a­sone alone.

Exciting data on the CD38 anti­bodies daratumumab and

The Beacon is pleased to introduce our newest myeloma thought leader col­um­nist, Dr. Ravi Vij. Every three months, Dr. Vij will share with us a new edition of “The Myeloma Quiz,” which will test your knowledge and under­standing of the myeloma-related research published during the pre­vi­ous several months.

We hope you will join us in welcoming Dr. Vij to the Beacon community, and in thank­ing him for sharing with us his valuable perspectives.

The relentless grind in the battle …